Does Humana Cover Trazodone?

Humana Formulary Placement for Trazodone

Generic trazodone hydrochloride is one of the most widely covered antidepressants across U.S. payers, and Humana is no exception. On the majority of Humana commercial PPO, HMO, and Medicare Advantage prescription drug plans (MA-PDs), trazodone appears on Tier 1 (preferred generic) or Tier 2 (non-preferred generic). The practical difference between these tiers is usually $3 to $10 in copay.

Because trazodone lost patent protection decades ago, no Humana plan currently requires members to use a brand-name version. The branded product Desyrel is effectively discontinued from most pharmacy shelves. Pharmacies almost universally dispense the generic, which the FDA considers therapeutically equivalent to the reference listed drug.

For members enrolled in Humana's Medicare Advantage Part D plans, CMS requires that all antidepressants in the "protected class" be available on formulary. The CMS Medicare Prescription Drug Benefit Manual identifies antidepressants as one of six protected classes, meaning Humana cannot exclude trazodone from its Part D formulary. This rule does not guarantee the lowest tier, but it does guarantee access.

One exception applies to Humana's employer-sponsored group plans, where self-funded employers can customize formulary tiers. In these arrangements, a plan sponsor could theoretically move trazodone to a higher tier or apply quantity limits. Members should verify placement by checking their specific plan's formulary document on Humana's online formulary lookup tool.

Prior Authorization Requirements

For the FDA-approved indication of major depressive disorder (MDD), Humana does not generally require prior authorization for generic trazodone. The drug's low cost, long safety record, and protected-class status on Medicare plans make PA requirements economically and regulatorily unnecessary for this indication.

Off-label prescribing is where the picture gets more complicated. Trazodone is one of the most frequently prescribed medications for insomnia in the United States. A retrospective cohort analysis found that trazodone was prescribed off-label for sleep in roughly 50% of cases [1]. Despite this widespread practice, the evidence base for insomnia monotherapy is thinner than many patients assume. Mendelson's review in the Journal of Clinical Psychiatry (2005) noted that only a small number of controlled trials supported trazodone for primary insomnia, with most showing modest improvements in sleep latency at doses of 50 to 100 mg [2].

Some Humana Medicare Advantage plans apply utilization management flags when the diagnosis code submitted is a sleep disorder rather than MDD. This does not always result in a formal PA request. Sometimes it triggers a "soft edit" at the pharmacy, which the pharmacist can override by confirming the prescriber's intent. Other times, the plan sends a PA request to the prescribing clinician.

If your prescriber receives a PA request, the typical turnaround is 24 to 72 hours. Humana's standard PA form asks for the diagnosis, prior medications tried, and clinical rationale. For insomnia specifically, the plan may ask whether the patient has tried or failed a first-line hypnotic such as zolpidem or eszopiclone, or whether cognitive behavioral therapy for insomnia (CBT-I) was attempted. The American Academy of Sleep Medicine (AASM) clinical practice guidelines recommend CBT-I as first-line treatment for chronic insomnia disorder [3].

Step Therapy: Does Humana Require It for Trazodone?

Step therapy (sometimes called "fail first") is a utilization management strategy where a plan requires a patient to try one or more lower-cost medications before covering a more expensive alternative. Because trazodone is already one of the lowest-cost antidepressants available, Humana rarely applies step therapy to it. The drug is itself often the "step one" medication that plans require before approving costlier agents.

There is one scenario where something resembling step therapy might appear. If a prescriber writes for the extended-release formulation of trazodone (trazodone ER, brand name Oleptro), Humana may require documentation that the patient tried and failed immediate-release trazodone first. Oleptro carries a significantly higher cost. The FDA-approved labeling for trazodone ER indicates it is dosed once daily at bedtime for MDD, typically starting at 150 mg with titration up to 375 mg [4].

For standard immediate-release trazodone tablets at 50 mg, 100 mg, or 150 mg strengths, no step therapy protocol is in effect on any currently published Humana commercial or MA-PD formulary.

What Trazodone Costs With Humana Insurance

The out-of-pocket cost for trazodone with Humana insurance depends on your plan's tier structure and your current deductible status. Here is a general breakdown:

On Humana commercial plans (employer-sponsored or ACA marketplace), Tier 1 generics typically carry a $0 to $10 copay after any applicable deductible. Many Humana commercial plans waive the deductible for Tier 1 generics entirely, meaning trazodone costs as little as $0 from day one of the plan year.

On Humana Medicare Advantage Part D plans, the Initial Coverage Phase copay for Tier 1 generics is commonly $0 to $5 for preferred pharmacies and $5 to $15 for non-preferred pharmacies. During the Coverage Gap (the "donut hole"), Medicare beneficiaries pay 25% of the negotiated price for generic drugs. For trazodone, 25% of a roughly $10 negotiated price means approximately $2.50 per month even in the gap.

Without insurance, the cash price for a 30-day supply of trazodone 50 mg (30 tablets) averages approximately $10 at major chain pharmacies. This makes trazodone one of the rare prescription medications where the uninsured cash price is comparable to the insured copay. GoodRx and similar discount programs sometimes offer prices as low as $4 for the same supply. The National Library of Medicine's DailyMed resource provides current labeling and pricing benchmarks [5].

How to Appeal a Humana Denial of Trazodone

Denials for trazodone are uncommon, but they do happen. The most frequent denial reasons include: missing diagnosis code, off-label indication not supported by compendia, quantity exceeding plan limits (typically 90 tablets per 30 days at the 50 mg strength), or formulary exclusion on a narrow employer-sponsored plan.

The appeal process differs depending on whether you are on a commercial plan or a Medicare Advantage plan.

Commercial plan appeal process. You or your prescriber files an internal appeal with Humana within 180 days of the denial. Include a letter of medical necessity from the prescriber, relevant chart notes, and documentation of any prior medications tried. Humana must respond within 30 days for a standard appeal or 72 hours for an expedited (urgent) appeal. If the internal appeal is denied, you can request an external review through your state's insurance department.

Medicare Advantage appeal process. The first level is a plan-level redetermination, filed within 60 days of the coverage determination. Humana must decide within 7 days (or 72 hours if expedited). If denied again, the case goes to an Independent Review Entity (IRE). For Medicare Part D drug coverage disputes, the IRE is MAXIMUS Federal Services. MAXIMUS reviews the case de novo and must decide within 7 days. Beyond MAXIMUS, beneficiaries can appeal to an Administrative Law Judge (ALJ) if the amount in controversy meets the CMS threshold, which was $190 for 2025 [6].

A practical tip: if your prescriber documents trazodone under the MDD diagnosis code (ICD-10 F32.x or F33.x) rather than an insomnia code (G47.0x), the likelihood of denial drops significantly. This is clinically appropriate when the patient has comorbid depression and insomnia, which describes the majority of trazodone users. The American Psychiatric Association Practice Guidelines note that trazodone is a reasonable adjunct for patients with MDD who experience residual insomnia [7].

Trazodone for Insomnia: Coverage Nuances on Humana

Trazodone's off-label use for insomnia is so common that many patients do not realize it lacks an FDA indication for this purpose. The FDA-approved prescribing information lists the sole indication as major depressive disorder [4]. This regulatory gap creates a specific coverage vulnerability.

Humana, like all Medicare Part D sponsors, is bound by CMS rules that permit off-label coverage only when the use is supported by at least one CMS-recognized compendia. The relevant compendia include the American Hospital Formulary Service Drug Information (AHFS-DI), Micromedex DrugDex, and the Lexi-Drugs Clinical Evaluation Monographs. Trazodone for insomnia is listed in AHFS-DI with a "reasonable" evidence rating, which satisfies the compendia requirement in most cases.

A 2017 meta-analysis published in the Journal of Clinical Medicine examined nine randomized controlled trials of trazodone for insomnia. The pooled data showed statistically significant improvements in subjective sleep quality, though effect sizes were modest (standardized mean difference 0.34 to 95% CI 0.04 to 0.64) [8]. Prescribers who cite this evidence in PA requests tend to receive approvals more readily.

For patients whose primary complaint is insomnia without depression, the prescriber should document why first-line insomnia treatments are contraindicated or have failed. The AASM guidelines list suvorexant, lemborexant, ramelteon, doxepin (low-dose), and CBT-I as recommended therapies for chronic insomnia [3]. Demonstrating trial and failure of at least one of these strengthens any PA or appeal.

Using a Manufacturer Savings Card With Humana

Because trazodone is a generic medication, no manufacturer savings card or copay assistance program currently exists for it. Savings cards are typically offered by brand-name manufacturers to offset higher copays, and they serve no purpose when the generic already costs $4 to $15 at retail.

Patients on Humana Medicare Advantage plans should also be aware that CMS prohibits the use of manufacturer copay cards for Medicare beneficiaries, regardless of whether a card exists. This rule applies to all Part D covered drugs. Violations can result in penalties for both the manufacturer and the pharmacy.

If cost is still a concern, Humana offers a mail-order pharmacy option (CenterWell Pharmacy, formerly Humana Pharmacy) that provides 90-day supplies of Tier 1 generics at reduced copays. For trazodone, a 90-day supply through CenterWell typically costs $0 to $12, compared to $0 to $15 for a single 30-day fill at a retail pharmacy [9]. The CenterWell Pharmacy website allows members to check pricing for their specific plan.

For uninsured or underinsured patients, several patient assistance programs accept applications for generic medications. NeedyMeds and RxAssist maintain databases of available programs, though trazodone's low baseline cost means most applicants are better served by pharmacy discount programs.

Quantity Limits and Dosing Considerations

Humana applies quantity limits to trazodone that align with FDA-approved maximum dosing. For immediate-release trazodone, the maximum FDA-approved dose for outpatient use is 400 mg per day (600 mg per day in inpatient settings). Most Humana plans set a quantity limit of 120 tablets per 30 days for the 100 mg strength, which accommodates a 400 mg daily dose.

For the 50 mg strength, limits are usually set at 240 tablets per 30 days, again reflecting the 400 mg ceiling. Prescriptions exceeding these quantities will trigger an automatic rejection at the pharmacy, requiring a quantity limit exception request.

A clinical consideration relevant to coverage: trazodone at antidepressant doses (150 to 400 mg per day) carries a different side-effect profile than trazodone at hypnotic doses (25 to 100 mg per day). The FDA safety communication regarding QT prolongation risk applies primarily to higher doses. A 2013 study in the Journal of Clinical Psychopharmacology found that trazodone doses above 300 mg per day were associated with a small but measurable increase in QTc interval (mean increase 10 ms, 95% CI 5 to 15 ms) [10]. Prescribers should document ECG monitoring for patients on high-dose regimens, as this documentation supports coverage for the higher quantities.